Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Phase of Trial: Phase III
Latest Information Update: 02 Jul 2016
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 29 Apr 2015 New trial record
- 20 Apr 2015 Changed planned end date from 1 Mar 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.